Roche today announced that the U.S. FDA has provided further guidance on the requirements for the Biologics License Application for ACTEMRA (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
The details can be read here.
No comments:
Post a Comment